P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY
E. Bachy,K. J. Savage,Hongbing Huang,Yok‐Lam Kwong,Giuseppe Gritti,Q. Zhang,A. M. Liberati,J. Cao,Hanxiang Yang,Hao Shen,Jinxing Hu,Keshu Zhou,Filomena Russo,H. Zhang,W. Sang,J. Ji,Andrés J.M. Ferreri,G. L. Damaj,H. Liu,Wen Zhang,Xianghan Ke,Chiara Ghiggi,Sha Huang,Xinyu Li,Hui Yao,J. Paik,W. Novotny,Wu Zhou,Hongjie Zhu,J. Huang,Pier Luigi Zinzani
DOI: https://doi.org/10.1097/01.hs9.0000847820.72232.2a
2022-01-01
HemaSphere
Abstract:Background: Effective treatment choices for patients (pts) with relapsed/refractory (R/R) mature T- and NK-cell neoplasms after failure of standard therapies are limited. Tislelizumab (TIS), a humanized anti–PD-1 mAb, demonstrated outstanding efficacy and favorable safety in pts with R/R classical Hodgkin lymphoma or solid tumors. Aims: To evaluate the safety and efficacy of TIS in pts with R/R mature T- and NK-cell neoplasms. Methods: This was a global, multicenter, single-arm, open-label, phase 2 study (NCT03493451). Pts were enrolled into 3 cohorts stratified by the type of T- and NK-cell neoplasms to receive TIS 200 mg intravenously every 3 weeks until disease progression or intolerable toxicity. Eligible pts had ≥1 prior systemic therapy, disease progression during or after most recent therapy completion or refractory disease, Eastern Cooperative Oncology Group performance score ≤2, and life expectancy ≥6 mo. All pts gave informed consent. Primary endpoint was investigator-assessed overall response rate (ORR). Secondary endpoints included duration of response (DOR), complete response (CR) rate, progression-free survival (PFS), overall survival (OS) in cohorts 1 and 2, and safety. Results: A total of 77 pts were treated. Cohort 1 included 22 pts with R/R extranodal NK and T-cell lymphomas; cohort 2 included 44 pts with R/R mature T-cell neoplasms (21 peripheral T-cell lymphoma not otherwise specified, 11 angioimmunoblastic T-cell lymphoma, and 12 anaplastic large cell lymphoma); and cohort 3 included 11 pts with R/R cutaneous T-cell lymphomas (CTCL; stage ≥1B; 8 mycosis fungoides and 3 Sézary syndrome). Of all pts, 76.6% had advanced-stage disease, 51.9% had refractory disease, and 49.4% had ≥3 prior systemic regimens. Median treatment cycles for cohorts 1, 2, and 3 were 5 (range 1-37), 4.5 (range 1-38), and 17 (range 3-25), respectively. Cohort 3 had promising efficacy (median study follow-up [FU] 16.6 mo); ORR 45.5%; CR 9.1%; median DOR 11.3 mo (95% CI, 2.76-11.30); median PFS 16.8 mo (95% CI, 2.60-16.82); and median OS not reached (NR) (95% CI, 4.90-not estimable [NE]). Modest efficacy was reported in cohort 1 (median study FU 8.4 mo): ORR 31.8%; CR 18.2%; median DOR NR (95% CI, 2.66-NE); median PFS 2.7 mo (95% CI, 1.45-5.32); and median OS 8.8 mo (95% CI, 3.25-NE). Modest efficacy also was noted in cohort 2 (median study FU 9.3 mo): ORR 20.5%; CR 9.1%; median DOR 8.2 mo (95% CI, 2.50-NE); median PFS 2.7 mo (95% CI, 2.56-4.76); and median OS 13.3 mo (95% CI, 7.66-26.22). Most frequent adverse events (AEs) were pyrexia (32.5%), anemia (18.2%), arthralgia (18.2%), and diarrhea (15.6%); most frequent grade ≥3 AEs were anemia (7.8%), pneumonia (6.5%), and neutropenia (5.2%). Any-grade immune-mediated AEs occurred in 22 (28.6%) pts, most frequently hypothyroidism (10.4%), hyperglycemia (5.2%), and rash (5.2%). Grade ≥3 AEs occurred in 4 (5.2%) pts and included increased blood creatine phosphokinase, hepatitis, hypothyroidism, rash, and urticaria (1 pt each). No treatment-related AEs led to death. Summary/Conclusion: TIS was well tolerated, achieving modest efficacy in R/R mature T- and NK-cell neoplasms, with some long-lasting remissions particularly in CTCL. Further studies are needed to determine the biologic features associated with response and explore optimal combination therapies.